Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
RS Herbst, YL Wu, T John, C Grohe… - Journal of Clinical …, 2023 - ingentaconnect.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
RS Herbst, YL Wu, T John, C Grohe, M Majem, J Wang… - 2023 - ahro.austin.org.au
The phase III ADAURA (ClinicalTrials. gov identifier: NCT02511106) primary analysis
demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant …
demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant …
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
RS Herbst, YL Wu, T John, C Grohe… - Journal of Clinical …, 2023 - mahidol.elsevierpure.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
RS Herbst, YL Wu, T John, C Grohe… - Journal of Clinical …, 2023 - europepmc.org
Purpose The phase III ADAURA (ClinicalTrials. gov identifier: NCT02511106) primary
analysis demonstrated a clinically significant disease-free survival (DFS) benefit with …
analysis demonstrated a clinically significant disease-free survival (DFS) benefit with …
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
RS Herbst, YL Wu, T John, C Grohe, M Majem, J Wang… - 2023 - pubmed.ncbi.nlm.nih.gov
Purpose The phase III ADAURA (ClinicalTrials. gov identifier: NCT02511106) primary
analysis demonstrated a clinically significant disease-free survival (DFS) benefit with …
analysis demonstrated a clinically significant disease-free survival (DFS) benefit with …
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non??? Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
RS Herbst, W Yi-Long, T John, C Grohe… - JOURNAL OF …, 2023 - research.unipd.it
Purpose: The phase III ADAURA (ClinicalTrials. gov identifier: NCT02511106) primary
analysis demonstrated a clinically significant disease-free survival (DFS) benefit with …
analysis demonstrated a clinically significant disease-free survival (DFS) benefit with …
[HTML][HTML] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
RS Herbst, YL Wu, T John, C Grohe… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
RS Herbst, YL Wu, T John, C Grohe… - Journal of Clinical …, 2023 - europepmc.org
The phase III ADAURA (ClinicalTrials. gov identifier: NCT02511106) primary analysis
demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant …
demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant …